With final appropriations bills still undecided, R&D funding, combined with the Administration’s budget in the remaining departments and agencies, totals currently at $147.9 billion, which is an increase of 0.56%. Unless there are some significant Congressional additions, we are headed toward a baseline FY2010 federal budget that fails to keep up with inflation.
Less than ten years ago, the U.S. was the epicenter of the pharmaceutical universe, with global firms establishing R&D centers throughout the U.S. to be near where the action was and build on the massive funding at the National Institutes of Health. But a funny thing happened over the past decade.
Over the past two years, the traditional leaders of R&D—the U.S., Europe, and Japan—have struggled to maintain the basic essentials of their economies and have seen their overall R&D programs slide in relation those of emerging economies. The big emerging nations—China, India, and Brazil—were not immune to the global recession.
The past several decades have heralded a revolution in the fundamental understanding of disease and disease progression. In particular, researchers have come to recognize the interconnectivity that exists between cellular tissue and organ systems in mammals, and that one system can no longer be studied in isolation.
As we have discussed in many recent forecasts, the concept, perception, and impact of R&D “outsourcing” is extremely complex, with ties to high-profile headlines, emotional concerns, bottom-line viability, and even patriotic banter. Depending on one’s perspective, outsourcing is negatively seen as the loss of jobs, R&D leadership, and competiveness, or positively seen as “open innovation,” support for industry/university collaborative research, and global market reach.
The greatest impact on our energy infrastructure in the near future will come from research and development focused on global climate change. Numbers bear this out.
Battelle recognized the potential for linking its U.S. operations to global research and development years ago and decided in 2005 to open operations in Asia to develop capabilities and laboratories to serve the region’s global markets.
The recession appears to have ended in most countries, with a return to positive economic and R&D growth. For most "advanced economies," this positive growth is likely to be relatively small, from 0.5% to 3.5% GDP growth.
The following Web sites are good sources of information related to the global R&D enterprise
Pentek is introducing two beamformer PCIe modules to its expansive product line. Each is a high-speed software radio board for processing baseband RF or IF signals and incorporates powerful beamforming functions. Created to accelerate system level design and lower system cost, the boards bring high-performance built-in features and connectivity to PC platforms.
EDAX Inc. has launched its TEAM EDS system that puts the knowledge of an EDS expert into every analysis system. TEAM EDS with Smart Features provides analytical intelligence that allows users to obtain higher quality and more reliable results.
The virtual working environment—a fancy term for the computer desktop—can be a sensitive subject for designers and engineers. It is the place where most of today’s developers spend much of their time, and it is rapidly becoming the place where valuable time and effort is lost in the research and development process.
In life science applications, sample preparation is crucial to any research project. With that knowledge, Symyx (Sunnyvale, Calif.) created a benchtop platform system that excels in doing complex sample preparation for a variety of life science analytics.
When using a fluorescence imaging microscope, a staple for life science research, researchers usually have to invest in dark rooms. Knowing that researchers’ time is precious, as well as the space they work in, Olympus created the FSX100 and the FluoView FV10i microscopes, that allow researchers to actually save space in laboratories and remove the need for dark rooms for fluorescence imaging experiments.
While some companies make the decision to take floor-standing instruments down to the benchtop, other companies market their analytical products for the benchtop initially. One such company is Shimadzu Scientific Instruments. Benefiting the pharmaceutical, food and beverage, environmental, biochemistry, and polymer industries, the new UV-1800 is part of Shimadzu’s natural progression of spectrophotometers.